Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $50.2 million.

  • Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) rose 5.30% to $50.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year increase of 5.30%. This contributed to the annual value of $48.0 million for FY2024, which is 2.98% up from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $50.2 million, which was up 1.42% from $49.5 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $50.2 million for Q3 2025, and its period low was $30.4 million during Q1 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $47.1 million in 2024 and averaged $45.4 million.
  • Data for Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 26.43% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $30.6 million in 2021, then rose by 20.34% to $36.9 million in 2022, then grew by 26.43% to $46.6 million in 2023, then climbed by 2.98% to $48.0 million in 2024, then increased by 5.30% to $50.2 million in 2025.
  • Its last three reported values are $50.2 million in Q3 2025, $49.5 million for Q2 2025, and $49.0 million during Q1 2025.